Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.43 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844999 | 0.88 | KIT (0.49) | GRIA1KITACHEGBA1PDE10A | |
| SCHEMBL17861324 | 0.88 | GRIA1 (0.55) | GRIA1KITACHETLR9GBA1 | |
| SCHEMBL12601536 | 0.88 | BACE1 (0.51) | GRIA1KITACHETLR9GBA1 | |
| SCHEMBL3682487 | 0.85 | KIT (0.47) | GRIA1KITACHETLR9GBA1 | |
| SCHEMBL1255986 | 0.85 | ACHE (0.59) | GRIA1KITACHEGBA1GPR119 | |
| SCHEMBL12601535 | 0.84 | PDE10A (0.51) | GRIA1KITACHETLR9GBA1 | |
| SCHEMBL12601534 | 0.82 | KIT (0.52) | GRIA1KITACHETLR9GBA1 | |
| SCHEMBL1774286 | 0.82 | KIT (0.45) | GRIA1KITACHETLR9GBA1 | |
| SCHEMBL1775580 | 0.81 | CNR1 (0.45) | GRIA1KITACHEGBA1PDE10A | |
| SCHEMBL1775930 | 0.81 | KIT (0.46) | GRIA1KITACHETLR9GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| CN-1922171-B | Pyrimidine derivative | ASKA PHARM CO LTD | 2012-10-17 | — | — | CN | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| CN-1922171-A | Pyrimidine derivatives | ASKA PHARM CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | GRIA1 1544/4885KIT 440/4885ACHE 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.